Clinical trials
for patients

The primary objective of this trial is to determine whether RO7589831 administered at different doses has effects, whether positive or negative, as well as what happens to RO7589831 once it enters the body and how it acts in the body and on your disease.

The objective of this study is to determine what dose of the study drug, called “CABA-201,” can be safely administered to patients with idiopathic inflammatory myopathy (IIM) and juvenile idiopathic inflammatory myopathy (JIIM) or myositis. Although the cause is not well understood, JIIM and some subtypes of IIM, including dermatomyositis (DM), antisynthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), are believed to involve B cells, which cause the body to attack differen...

This study is being conducted to determine whether the study drug, momelotinib, works to improve anemia, a condition associated with myelodysplastic syndrome (MDS); whether it makes you feel better; whether it is safe and well tolerated; and which dose of the drug works best. This study will be conducted in adult participants aged 18 years and older with anemia associated with MDS.

The objective is to study the samples to understand their responses to the study drug and to obtain more information about small cell lung cancer.

The primary objective is to evaluate the safety and tolerability of GSK5533524 as monotherapy in PROC and to select the dose(s) for evaluation in Part 1b.

The objective of this research is to evaluate whether the study drug NI-1801, as a single agent, in combination with pembrolizumab, in combination with paclitaxel (randomized cohort I), or in combination with pembrolizumab and standard chemotherapy-based treatment with paclitaxel (randomized cohort II), has potential beneficial effects and is safe for patients with these types of cancer.

The objective of this study is to evaluate potential new cancer treatments for people with tumors similar to yours. The sponsor wants to find out what effects, positive or negative, these treatments have on you and your disease.

The objective of this trial is to provide continued treatment with remibrutinib and collect long-term safety data in patients who have completed a Novartis remibrutinib trial, who have benefited from treatment, and who cannot obtain remibrutinib locally.

This study is designed to help us determine whether the study drug BMS-986517 works to treat advanced solid tumors. Experts are continuing to investigate BMS-986517 to learn about its side effects and efficacy. The study drug has not yet been approved by the Food and Drug Administration (FDA) or other regulatory agencies for the treatment of advanced solid tumors or any other medical condition.

The objective of this study is to determine whether an investigational drug called MB-CART2019.1 is more effective than a second standard chemotherapy treatment for your disease. This study will also investigate the safety of MB-CART2019.1 when administered to patients and will determine whether there are any changes in their quality of life.

The objective of this study is to provide continued access to elranatamab (as monotherapy) and to monitor the safety of this drug in participants with multiple myeloma who continue to show clinical benefits in the Pfizer-sponsored main study, which is scheduled to conclude.

The objective of this study is to determine the safety and efficacy of a new drug called “visugromab” when administered in combination with immunochemotherapy

The aim of this trial is: -To see whether the new treatment BAY 3713372 has any effect, good or bad. -To find the best dose of BAY 3713372 to give to participants. -To understand what happens to BAY 3713372 once it is in the body. -To understand how the drug affects your body. -To understand how the treatment affects your disease. -To learn how different types and amounts of food affect the way the body absorbs the trial drug.

The aim of this clinical trial is to determine the efficacy of a new drug called “visugromab” (also known as “CT-L002”) and its safety when administered in combination with nivolumab and docetaxel. CT-L002 and nivolumab help the immune system fight cancer. Docetaxel interferes with the growth of cancer cells, leading to their destruction. CT-L002 has not yet been approved for any patients outside research studies.

The aim of this study is to evaluate the efficacy, safety and tolerability of Temab-A as monotherapy in patients with locally advanced or metastatic solid tumors with MET gene amplification.

The purpose of this trial is to determine how well a new drug currently in development called visugromab (also known as CTL-002) works and whether it is safe when used in combination with nivolumab and lenvatinib.

The objective of this study is to evaluate the long-term tolerability and safety of the investigational drug TEV-56286 in people with AMS.

The primary objective of this study is to determine whether STK-012 administered together with standard-of-care treatment is more effective in treating cancer than standard-of-care treatment alone in patients with lung cancer. STK-012 is a new investigational drug being studied by the sponsor.

The objective of this trial, which involves research, is to examine the safety and efficacy of an investigational drug called LB-208. Investigational means that the investigational drug to be tested in this clinical trial has not been authorized by national drug regulatory agencies, such as the Spanish Agency of Medicines and Medical Devices.

Phase I study to determine the safety and tolerability of BI 3820768 in patients with advanced, relapsed, or treatment-refractory germ cell tumors, endometrial cancer, or ovarian cancer.